NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Drug Manufacturers - Specialty & Generic · USD

Biofrontera Inc. (BFRI) Stock Analysis

Biofrontera Inc. (BFRI) is a Drug Manufacturers - Specialty & Generic stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

BFRI

$0.80

−$0.00 (−0.50%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare BFRI with… →

BFRI Key Statistics

As of Oct 21, 2026
Trading
Open
$0.80
Previous Close
$0.80
Day's Range
0.80–0.81
52-Week Range
0.56–1.66
Volume
129.98K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.88
Valuation
Market Cap
$11.94M
P/E Ratio
unprofitable
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
1.87
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
0.26
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.43
Financials (FY)
Revenue (FY)
$41.71M+11.75%
Net Income (FY)
−$10.54M
Profit marginThe share of revenue left as profit after all costs and taxes.
−13.79%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
14.85M
1-Year Return
−19.76%
Dividend and dates
Earnings Date
November 11, 2026
Avg Volume
544.55K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, BFRI closed at $0.80, −19.76% over 1 year.

Biofrontera Inc. (BFRI) has a market capitalization of $11.94M.

In fiscal 2025, BFRI reported revenue of $41.71M.

BFRI Stock Return by Calendar Year

Biofrontera Inc. (BFRI) return since Oct 2021: what $10,000 became

1 year
$10,000 $8,024
−19.76%
5 years
$10,000 $91
−99.09%

If you had invested $10,000 in Biofrontera Inc. (BFRI) at the close on October 29, 2021, the earliest close on record here, it would have been worth $91 at the close on October 21, 2026: −99.09% in total, −60.96% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+40.35%
2025−47.71%
2024−60.65%
2023−84.90%
2022−87.81%
2021 (partial year)+70.52%

As of October 21, 2026.

BFRI Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$41.71M−$10.54M−25.3%
2024$37.32M−$17.76M−47.6%
2023$34.07M−$20.13M−59.1%
2022$28.67M−$640.00K−2.2%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$41.71M$30.74M−$11.35M−$10.54M−25.3%
2024$37.32M$18.71M−$17.21M−$17.76M−47.6%
2023$34.07M$16.63M−$22.58M−$20.13M−59.1%
2022$28.67M$13.49M−$22.38M−$640.00K−2.2%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

BFRI Valuation vs Drug Manufacturers - Specialty & Generic Median

Median of 97 stocks
MetricBFRIDrug Manufacturers - Specialty & Generic medianvs median
P/S ratio0.262.100.1x the median
Profit margin−13.79%−8.14%5.6 pts below

Medians across 97 Drug Manufacturers - Specialty & Generic stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 12 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Biofrontera Inc. (BFRI) is capitalised at $11.94M on the latest close. The company sits in the Healthcare sector, in the Drug Manufacturers - Specialty & Generic industry. Headcount on file is 84.

BFRI last closed at $0.80 on October 21, 2026. That is $0.00 (−0.50%) against the previous close. The 52-week range on file runs from $0.56 to $1.66. The latest close sits 44.14% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $41.71M. Against the prior fiscal year total of $37.32M, that is a change of +11.75%. The same year closed with a net loss of $10.54M. The reported profit margin is −13.79%. That is 5.6 percentage points below the Drug Manufacturers - Specialty & Generic median of −8.14%. Earnings per share on a trailing basis come to −0.43.

Across the 4 fiscal years on file, revenue moves from $28.67M in 2022 to $41.71M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The forward P/E on file is 1.87. Measured against sales, the shares trade at 0.26 times revenue. On price-to-sales that is 0.1 times the Drug Manufacturers - Specialty & Generic median of 2.1. The medians here are taken across 97 Drug Manufacturers - Specialty & Generic companies that report the metric.

The reported beta is 0.88. Annualized volatility over the trailing 5 years is 120.89%. Over the trailing twelve months the total return is −19.76%. Measured over 5 years, that is −60.96% a year compounded.

Growth & Income

The record shows no dividend for BFRI.

2026 is still running; the total return is +40.35% year to date. Across the complete calendar years on file, 2025 returned −47.71% and 2022 returned −87.81%. Of the 4 complete calendar years on file, 0 finished higher.

Peer Comparison

Biofrontera Inc. (BFRI) operates in the Drug Manufacturers - Specialty & Generic industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Biofrontera Inc. BFRI $11.94M —
Takeda Pharmaceutical Company Limited TAK $63.67B —
Teva Pharmaceutical Industries Limited TEVA $47.37B 67.7
Haleon plc HLN $44.06B 20.5

The Drug Manufacturers - Specialty & Generic industry average P/E ratio is 20.3x. Biofrontera Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Drug Manufacturers - Specialty & Generic Stocks

TAK

Takeda Pharmaceutical Company Limited

$63.67B

 TEVA

Teva Pharmaceutical Industries Limited

$47.37B

 HLN

Haleon plc

$44.06B

 ZTS

Zoetis Inc.

$32.90B

 UTHR

United Therapeutics Corporation

$24.17B

 VTRS

Viatris Inc.

$21.19B
View all Drug Manufacturers - Specialty & Generic stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Biofrontera Inc.

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Visit website →